Purple pitcher plant
Identification
- Generic Name
- Sarracenia Purpurea
Commonly known or available as Purple pitcher plant - DrugBank Accession Number
- DB13965
- Background
Sarracenia purpurea, commonly known as the purple pitcher plant, northern pitcher plant, turtle socks, or side-saddle flower, is a perennial carnivorous plant in the family Sarraceniaceae. Sarracenia purpurea attract and trap insects within their pitchers, or fused leaves, to consume nitrogen during the digestion process 1. It is widely distributed across North America and has been used as a traditional medicinal herb in many aboriginal communities 1,2. It was used as an injectable pain reliever and during the 19th century, Sarracenia purpurea was used as a treatment of smallpox 1. Compounds extracted from Sarracenia purpurea include phenolic glycosides, flavonoid glycosides, and iridoids. In vitro, there is evidence of glycosides potentiating glucose uptake with potential antidiabetic properties 2. Cytoprotection in an in vitro model of diabetic neuropathy has also been studied. However, the use of Sarracenia Purpurea extracts in the clinical setting are limited.
- Type
- Biotech
- Groups
- Approved, Experimental
- Synonyms
- Frog's-britches whole
- Huntsman's-horns whole
- Pitcher plant
- Pitcherplant whole
- Purple pitcherplant whole
- Sarracenia purpura
- Sarracenia purpurea l.
- Sarracenia purpurea whole
- Sarracenia rosea whole
- Sidesaddle-flower whole
Pharmacology
- Indication
No approved therapeutic indications.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Pain •••••••••••• ••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Extracts of Sarracenia purpurea may enhance glucose uptake by attenuating glucose-6-phosphatase enzymatic activity and decreasing hepatic glucose production 2. In an in vitro model of glucotoxicity in PC12 cells, treatment of Sarracenia purpurea demonstrated cytoprotective effects and prevented glucose-mediated cell loss 1.
- Mechanism of action
The full mechanism of action of the antidiabetic and cytoprotective activity is not fully elucidated.
- Absorption
No pharmacokinetic data available.
- Volume of distribution
No pharmacokinetic data available.
- Protein binding
No pharmacokinetic data available.
- Metabolism
No pharmacokinetic data available.
- Route of elimination
No pharmacokinetic data available.
- Half-life
No pharmacokinetic data available.
- Clearance
No pharmacokinetic data available.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
No toxicokinetic data available.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image P-Bloc Injection 12.5 mg/1mL Parenteral Creative Science, Llc 2004-11-20 2019-07-01 US Sarapin Injection 0.17 g/1mL Intramuscular High Chemical Company 1935-01-31 2016-06-10 US Sarapin Solution 100 % Intramuscular High Chemical Company 1942-12-31 2019-04-30 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image P-Bloc Sarracenia Purpurea (12.5 mg/1mL) Injection Parenteral Creative Science, Llc 2004-11-20 2019-07-01 US Sarapin Sarracenia Purpurea (0.17 g/1mL) Injection Intramuscular High Chemical Company 1935-01-31 2016-06-10 US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FOP08H143P
- CAS number
- Not Available
References
- General References
- Harris CS, Asim M, Saleem A, Haddad PS, Arnason JT, Bennett SA: Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells. BMC Complement Altern Med. 2012 Dec 5;12:245. doi: 10.1186/1472-6882-12-245. [Article]
- Muhammad A, Guerrero-Analco JA, Martineau LC, Musallam L, Madiraju P, Nachar A, Saleem A, Haddad PS, Arnason JT: Antidiabetic compounds from Sarracenia purpurea used traditionally by the Eeyou Istchee Cree First Nation. J Nat Prod. 2012 Jul 27;75(7):1284-8. doi: 10.1021/np3001317. Epub 2012 Jun 27. [Article]
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Parenteral 12.5 mg/1mL Injection Intramuscular 0.17 g/1mL Solution Intramuscular 100 % - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at January 17, 2018 18:40 / Updated at March 28, 2024 03:23